{"nctId":"NCT00981682","briefTitle":"Long Term Safety Assessment of SER120 in Patients With Nocturia","startDateStruct":{"date":"2009-08"},"conditions":["Nocturia"],"count":376,"armGroups":[{"label":"SER120 (desmopressin)","type":"EXPERIMENTAL","interventionNames":["Drug: SER120"]}],"interventions":[{"name":"SER120","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients completed SPC-SER120-DB1-200901 and SPC-SER120-DB2-200902 studies\n* Willing to provide consent for the study\n\nExclusion Criteria:\n\n* Incontinence\n* Diabetes Insipidus, Diabetes Mellitus\n* CHF\n* Renal Insufficiency\n* Significant medical history which make participation unacceptable","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Serum Sodium","description":"Change in mean serum sodium on Day 8, Day 15, Day 22, Week 4, Week 8, Week 12, Week 20, Week 28 and Week 40 compared to Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"2.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":30,"n":376},"commonTop":["Nasal discomfort","sneezing","Rhinorrhea","headache","Upper respiratory infection"]}}}